The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Experimental autoimmune encephalomyelitis (EAE) mice were administered with murine anti-CD52 antibody to investigate its therapeutic effect and whether the treatment modulates IL-33 and ST2 expression. EAE severity and central nervous system (CNS) inflammation were reduced following the treatment, which was accompanied by peripheral T and B lymphocyte depletion and reduced production of various cytokines including IL-33, while sST2 was increased. In spinal cords of EAE mice, while the number of IL-33+ cells remained unchanged, the extracellular level of IL-33 protein was significantly reduced in anti-CD52 antibody treated mice compared with controls. Furthermore the number of ST2+ cells in the spinal cord of treated EAE mice was downregulated due to decreased inflammation and immune cell infiltration in the CNS. These results suggest that treatment with anti-CD52 antibody differentially alters expression of IL-33 and ST2, both systemically and within the CNS, which may indicateIL-33/ST2 axis is involved in the action of the antibody in inhibiting EAE.
LanguageEnglish
Pages1-33
Number of pages33
JournalJournal of Neuroimmunology
Early online date24 Feb 2018
DOIs
Publication statusE-pub ahead of print - 24 Feb 2018

Fingerprint

Autoimmune Experimental Encephalomyelitis
Therapeutic Uses
Anti-Idiotypic Antibodies
Central Nervous System
Spinal Cord
Lymphocyte Depletion
Inflammation
Therapeutics
B-Lymphocytes
Down-Regulation
Cell Count
Interleukin-33
Cytokines
T-Lymphocytes
Antibodies
Proteins

Keywords

  • multiple sclerosis
  • experimental autoimmune encephalomyelitis
  • CD52
  • IL-33
  • ST2

Cite this

@article{7fdd545161a34b59abac7fac5038eb29,
title = "The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels",
abstract = "Experimental autoimmune encephalomyelitis (EAE) mice were administered with murine anti-CD52 antibody to investigate its therapeutic effect and whether the treatment modulates IL-33 and ST2 expression. EAE severity and central nervous system (CNS) inflammation were reduced following the treatment, which was accompanied by peripheral T and B lymphocyte depletion and reduced production of various cytokines including IL-33, while sST2 was increased. In spinal cords of EAE mice, while the number of IL-33+ cells remained unchanged, the extracellular level of IL-33 protein was significantly reduced in anti-CD52 antibody treated mice compared with controls. Furthermore the number of ST2+ cells in the spinal cord of treated EAE mice was downregulated due to decreased inflammation and immune cell infiltration in the CNS. These results suggest that treatment with anti-CD52 antibody differentially alters expression of IL-33 and ST2, both systemically and within the CNS, which may indicateIL-33/ST2 axis is involved in the action of the antibody in inhibiting EAE.",
keywords = "multiple sclerosis, experimental autoimmune encephalomyelitis, CD52, IL-33, ST2",
author = "Mark Barbour and Rachel Wood and Hridi, {Shehla U} and Chelsey Wilson and Grant McKay and Bushell, {Trevor J} and Hui-Rong Jiang",
year = "2018",
month = "2",
day = "24",
doi = "10.1016/j.jneuroim.2018.02.012",
language = "English",
pages = "1--33",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",

}

TY - JOUR

T1 - The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels

AU - Barbour, Mark

AU - Wood, Rachel

AU - Hridi, Shehla U

AU - Wilson, Chelsey

AU - McKay, Grant

AU - Bushell, Trevor J

AU - Jiang, Hui-Rong

PY - 2018/2/24

Y1 - 2018/2/24

N2 - Experimental autoimmune encephalomyelitis (EAE) mice were administered with murine anti-CD52 antibody to investigate its therapeutic effect and whether the treatment modulates IL-33 and ST2 expression. EAE severity and central nervous system (CNS) inflammation were reduced following the treatment, which was accompanied by peripheral T and B lymphocyte depletion and reduced production of various cytokines including IL-33, while sST2 was increased. In spinal cords of EAE mice, while the number of IL-33+ cells remained unchanged, the extracellular level of IL-33 protein was significantly reduced in anti-CD52 antibody treated mice compared with controls. Furthermore the number of ST2+ cells in the spinal cord of treated EAE mice was downregulated due to decreased inflammation and immune cell infiltration in the CNS. These results suggest that treatment with anti-CD52 antibody differentially alters expression of IL-33 and ST2, both systemically and within the CNS, which may indicateIL-33/ST2 axis is involved in the action of the antibody in inhibiting EAE.

AB - Experimental autoimmune encephalomyelitis (EAE) mice were administered with murine anti-CD52 antibody to investigate its therapeutic effect and whether the treatment modulates IL-33 and ST2 expression. EAE severity and central nervous system (CNS) inflammation were reduced following the treatment, which was accompanied by peripheral T and B lymphocyte depletion and reduced production of various cytokines including IL-33, while sST2 was increased. In spinal cords of EAE mice, while the number of IL-33+ cells remained unchanged, the extracellular level of IL-33 protein was significantly reduced in anti-CD52 antibody treated mice compared with controls. Furthermore the number of ST2+ cells in the spinal cord of treated EAE mice was downregulated due to decreased inflammation and immune cell infiltration in the CNS. These results suggest that treatment with anti-CD52 antibody differentially alters expression of IL-33 and ST2, both systemically and within the CNS, which may indicateIL-33/ST2 axis is involved in the action of the antibody in inhibiting EAE.

KW - multiple sclerosis

KW - experimental autoimmune encephalomyelitis

KW - CD52

KW - IL-33

KW - ST2

UR - https://www.sciencedirect.com/journal/journal-of-neuroimmunology

U2 - 10.1016/j.jneuroim.2018.02.012

DO - 10.1016/j.jneuroim.2018.02.012

M3 - Article

SP - 1

EP - 33

JO - Journal of Neuroimmunology

T2 - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

ER -